http://www.mdpi.com/journal/pharmaceuticals/special_issues/tropical-medicine/ Submission Information All papers should be submitted to pharmaceuticals@mdpi.com. To be published continuously until the deadline and papers will be listed together at the special issue website. Submitted papers should not have been published nor be under consideration for publication elsewhere. All papers are refereed through a peer-review process. A guide for authors is available on the Instructions for Authors page. Pharmaceuticals is a new international, peer-reviewed, quarterly open access journal published by MDPI. Article Processing Charges (APC) for publication in this open access journal are waived for well-prepared manuscripts submitted by 30 June 2010. English correction or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those paper accepted for publication, that require extensive additional formatting and/or English corrections. http://www.mdpi.com/1424-8247/3/10/3212/ The flow of international travellers to and from malaria-endemic areas, especially Africa, has increased in recent years. Apart from the very high morbidity and mortality burden imposed on malaria-endemic areas, imported malaria is the main cause of fever possibly causing severe disease and death in travellers coming from tropical and subtropical areas, particularly Sub-Saharan Africa. The importance of behavioural preventive measures (bed nets, repellents, etc.), adequate chemoprophylaxis and, in selected circumstances, stand-by emergency treatment may not be overemphasized. However, no prophylactic regimen may offer complete protection. Expert advice is needed to tailor prophylactic advice according to traveller (age, baseline clinical conditions, etc.) and travel (destination, season, etc.) characteristics in order to reduce malaria risk. http://www.mdpi.com/1424-8247/3/10/3212/ Wed, 13 Oct 2010 00:00:00 CEST Pharmaceuticals 2010-10-13 3 10 Review 3212 3239 1424-8247 Malaria Prophylaxis: A Comprehensive Review 2010-10-13 doi: 10.3390/ph3103212 Francesco Castelli Silvia Odolini Beatrice Autino Emanuele Foca Rosario Russo http://www.mdpi.com/1424-8247/3/5/1561/ Travelers to tropical countries are at risk for a variety of infectious diseases. In some cases effective vaccinations are available, but for other infections chemoprophylaxis can be offered. Malaria prevention has become increasingly complex as Plasmodium species become resistant to available drugs. In certain high risk settings, antibiotics can be used to prevent leptospirosis, scrub typhus and other infections. Post-exposure prophylaxis is appropriate for selected virulent infections. In this article the evidence for chemoprophylaxis will be reviewed. http://www.mdpi.com/1424-8247/3/5/1561/ Tue, 18 May 2010 00:00:00 CEST Pharmaceuticals 2010-05-18 3 5 Review 1561 1575 1424-8247 Chemoprophylaxis of Tropical Infectious Diseases 2010-05-18 doi: 10.3390/ph3051561 McBride http://www.mdpi.com/1424-8247/3/5/1296/ Melioidosis is a complex bacterial infection, treatment of which combines the urgency of treating rapidly fatal Gram negative septicaemia with the need for eradication of long-term persistent disease in pulmonary, soft tissue, skeletal and other organ systems. Incremental improvements in treatment have been made as a result of multicentre collaboration across the main endemic region of Southeast Asia and northern Australia. There is an emerging consensus on the three main patterns of antimicrobial chemotherapy; initial (Phase 1) treatment, subsequent eradication (Phase 2) therapy and most recently post-exposure (Phase 0) prophylaxis. The combination of agents used, duration of therapy and need for adjunct modalities depends on the type, severity and antimicrobial susceptibility of infection. New antibiotic and adjunct therapies are at an investigational stage but on currently available data are unlikely to make a significant impact on this potentially fatal infection. http://www.mdpi.com/1424-8247/3/5/1296/ Tue, 27 Apr 2010 00:00:00 CEST Pharmaceuticals 2010-04-27 3 5 Review 1296 1303 1424-8247 The Treatment of Melioidosis 2010-04-27 doi: 10.3390/ph3051296 Inglis http://www.mdpi.com/1424-8247/3/4/810/ Chagas’ disease, or American trypanosomosiasis, has been the most relevant illness produced by protozoa in Latin America. Synthetic medicinal chemistry efforts have provided an extensive number of chemodiverse hits at the “active-to-hit” stage. However, only a more limited number of these have been studied in vivo in models of Chagas’ disease. Herein, we survey some of the cantidates able to surpass the “hit-to-lead” stage discussing their limitations or merit to enter in clinical trials in the short term. http://www.mdpi.com/1424-8247/3/4/810/ Thu, 25 Mar 2010 00:00:00 CET Pharmaceuticals 2010-03-25 3 4 Review 810 838 1424-8247 Synthetic Medicinal Chemistry in Chagas’ Disease: Compounds at The Final Stage of “Hit-To-Lead” Phase 2010-03-25 doi: 10.3390/ph3040810 Cerecetto González